Biotech and Pharmaceuticals Pharmaceuticals

  • First Ebola case diagnosed in US confirmed

    The CDC has confirmed the first Ebola case diagnosed in the U.S. and will hold a news conference at 5:30PM E.T. Tuesday. CNBC's Meg Tirrell has the details.

  • Health care inversions in jeopardy?

    Discussing how new government rules could impact health care inversion deals, with CNBC's Meg Tirrell and Les Funtleyder, Esquared Asset Management.

  • Roche breast cancer drug helped patients live longer

    A new breast cancer drug from Roche showed "unprecedented" benefits in a clinical trial, reports CNBC's Meg Tirrell.

  • Woman having a mammography scan.

    A new breast cancer drug from Roche has shown "unprecedented" benefits in extending lives in a clinical trial.

  • Positive data from Roche breast cancer drug

    A breast cancer drug from Roche known as Perjeta helped patients live nearly 16 months longer compared with Herceptin and chemotherapy alone. CNBC's Meg Tirrell provides insight to the data.

  • Medicins Sans Frontieres health workers at an isolation camp in Liberia during the visit of the UN Ebola systems coordinator, Aug. 23, 2014.

    The World Bank on Thursday announced it would give another $170 million to help West African countries contain the spread of the Ebola virus.

  • Tax crackdown impact on pharma deals

    Discussing how the Treasury Department's new rules to end tax inversions could impact the pharma deals, with Michael Faerm, Wells Fargo Securities.

  • The world's attention may have shifted to U.S. airstrikes on Syria, but West Africa continues to be ravaged by the worst outbreak of Ebola.

  • Salix & Allergan in serious talks

    CNBC's David Faber reports significant talks are taking place between Allergan and Salix Pharmaceuticals, and how the potential deal impacts Valeant. Jim Cramer explains how Wall Street perceives the potential buy.

  • The Merck KGaA logo sits outside the company's headquarters in Darmstadt, Germany.

    Merck agrees to acquire Sigma-Aldrich for $17 billion in cash to boost its life science business.

  • Germany's Merck to acquire Sigma-Aldrich for $17 billion

    Karl Ludwig-Kley Merck KGAA, and Rakesh Sachdev, Sigma-Aldrich president & CEO, discuss Merck's acquisition of Sigma-Aldrich and the future of life sciences and technology.

  • An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.

  • Ebola under the microscope

    CNBC's Meg Tirrell, and Scott Gottlieb, American Enterprise Institute, discuss the latest developments in controlling the Ebola epidemic.

  • U.S. regulators are greenlighting a new weight-loss drug called Contrave, the third in a string of approvals for anti-obesity treatments.

  • Bristol-Myers, Ono will win in patent fight: Pro

    Vamil Divan, Senior Analyst, U.S. Pharmaceuticals at Credit Suisse, discusses news that Bristol-Myers Squibb and Ono Pharmaceutical are suing Merck over the Keytruda cancer drug.

  • Accelerating Ebola vaccine

    CNBC's Meg Tirrell speaks to Johnson & Johnson chairman, Joaquin Duato, about J&J's partnership with the National Institutes of Health to fast track its Ebola vaccine program to begin human testing by early 2015.

  • CNBC's Andrea Day reports on a former convicted drug smuggler who has turned to selling diet supplements.

  • Infinity Pharma teams up with AbbVie for cancer drug

    Infinity Pharma will receive $275 million upfront from AbbVie, as part of a new venture to develop blood cancer treatments. Infinity CEO Adelene Q. Perkins, explains the significance of the deal, with CNBC's Meg Tirrell.

  • Biotech's $10 billion opportunity

    CNBC's Meg Tirrell reports experimental cholesterol medicines by Amgen and Regeneron represent a potential $10 billion opportunity pending FDA approval in the U.S.

  • Kite Pharma's positive cancer drug study results

    Kite Pharma is working on a treatment which involves taking a cancer patient's own t-cells out of their body, genetically modifying them to better target cancer, and then re-administering them. Its CEO Arie Belldegrun, provides insight to the positive study with the therapy.